Zimmer Biomet (NYSE:ZBH - Get Free Report) announced its quarterly earnings results on Monday. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.04, RTT News reports. The business had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The company's revenue was up 1.1% on a year-over-year basis. During the same quarter last year, the firm earned $1.94 EPS. Zimmer Biomet updated its FY 2025 guidance to 7.900-8.100 EPS.
Zimmer Biomet Stock Performance
NYSE ZBH traded up $2.05 on Wednesday, hitting $94.32. 2,662,430 shares of the company traded hands, compared to its average volume of 1,700,859. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The business's 50 day moving average price is $104.81 and its 200-day moving average price is $106.24. The company has a market capitalization of $18.66 billion, a price-to-earnings ratio of 21.20, a P/E/G ratio of 1.95 and a beta of 0.78. Zimmer Biomet has a 52-week low of $89.92 and a 52-week high of $122.25.
Zimmer Biomet Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Wednesday, April 30th. Investors of record on Monday, March 31st were issued a $0.24 dividend. The ex-dividend date was Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 1.02%. Zimmer Biomet's dividend payout ratio is currently 21.24%.
Insider Transactions at Zimmer Biomet
In related news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This represents a 14.13 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.39% of the company's stock.
Hedge Funds Weigh In On Zimmer Biomet
A hedge fund recently bought a new stake in Zimmer Biomet stock. Brighton Jones LLC purchased a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,936 shares of the medical equipment provider's stock, valued at approximately $204,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
ZBH has been the subject of a number of recent analyst reports. Needham & Company LLC reaffirmed a "hold" rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Wells Fargo & Company dropped their price target on Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating for the company in a research note on Tuesday. Raymond James decreased their price objective on shares of Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating for the company in a report on Tuesday. BTIG Research reiterated a "buy" rating on shares of Zimmer Biomet in a research report on Monday, April 14th. Finally, Robert W. Baird cut their price objective on Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating on the stock in a research report on Tuesday. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $114.15.
Get Our Latest Report on ZBH
About Zimmer Biomet
(
Get Free Report)
Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
Further Reading
Before you consider Zimmer Biomet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zimmer Biomet wasn't on the list.
While Zimmer Biomet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
